LivaNova PLCLIVNEarnings & Financial Report
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
LIVN Q4 FY2025 Key Financial Metrics
Revenue
$360.9M
Gross Profit
$235.3M
Operating Profit
$42.6M
Net Profit
$30.9M
Gross Margin
65.2%
Operating Margin
11.8%
Net Margin
8.6%
YoY Growth
12.1%
EPS
$0.57
LivaNova PLC Q4 FY2025 Financial Summary
LivaNova PLC reported revenue of $360.9M (up 12.1% YoY) for Q4 FY2025, with a net profit of $30.9M (down 44.7% YoY) (8.6% margin). Cost of goods sold was $125.7M, operating expenses totaled $192.7M.
Key Financial Metrics
| Total Revenue | $360.9M |
|---|---|
| Net Profit | $30.9M |
| Gross Margin | 65.2% |
| Operating Margin | 11.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
LivaNova PLC Q4 FY2025 revenue of $360.9M breaks down across 3 segments, led by Other at $169.4M (46.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $169.4M | 46.9% |
| Neuromodulation Segment | $119.7M | 33.2% |
| Cardiopulmonary Segment | $71.8M | 19.9% |
LivaNova PLC Revenue by Segment — Quarterly Trend
LivaNova PLC revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Neuromodulation Segment) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other | $169.4M | $167.4M | $164.1M | $147.7M |
| Neuromodulation Segment | $119.7M | $118.4M | $117.2M | $108.3M |
| Cardiopulmonary Segment | $71.8M | $71.9M | $71.2M | $60.8M |
LivaNova PLC Annual Revenue by Year
LivaNova PLC annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4B).
LivaNova PLC Quarterly Revenue & Net Profit History
LivaNova PLC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $360.9M | +12.1% | $30.9M | 8.6% |
| Q3 FY2025 | $357.8M | +12.5% | $26.8M | 7.5% |
| Q2 FY2025 | $352.5M | +10.7% | $27.2M | 7.7% |
| Q1 FY2025 | $316.9M | +7.4% | $-327.3M | -103.3% |
| Q4 FY2024 | $321.8M | +3.8% | $55.9M | 17.4% |
| Q3 FY2024 | $318.1M | +11.2% | $33.0M | 10.4% |
| Q2 FY2024 | $318.6M | +8.4% | $16.3M | 5.1% |
| Q1 FY2024 | $294.9M | +12.0% | $-41.9M | -14.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $294.9M | $318.6M | $318.1M | $321.8M | $316.9M | $352.5M | $357.8M | $360.9M |
| YoY Growth | 12.0% | 8.4% | 11.2% | 3.8% | 7.4% | 10.7% | 12.5% | 12.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.46B | $2.45B | $2.52B | $2.51B | $2.56B | $2.51B | $2.56B | $2.61B |
| Liabilities | $1.24B | $1.21B | $1.21B | $1.19B | $1.52B | $1.38B | $1.40B | $1.41B |
| Equity | $1.22B | $1.24B | $1.31B | $1.32B | $1.03B | $1.12B | $1.16B | $1.20B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $10.0M | $43.4M | $51.0M | $78.7M | $24.0M | $62.9M | $85.1M | $82.4M |